Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Intensive Care Medicine

The Treatment Plan: Attacking the Infection

At a Glance

Primary Amebic Meningoencephalitis (PAM) is treated in the ICU with an aggressive 5-drug cocktail including Amphotericin B, Miltefosine, Azithromycin, Fluconazole, and Rifampin. Critical care also focuses on managing severe brain swelling using pressure drains, steroids, and therapeutic cooling.

In the ICU, treating Primary Amebic Meningoencephalitis (PAM) is an all-hands-on-deck medical emergency. Because the ameba moves so quickly, the medical team uses an aggressive “cocktail” of multiple drugs at once to attack the organism from every possible angle [1][2]. This approach combines powerful antimicrobials with advanced neurocritical care to manage life-threatening brain swelling.

The Five-Drug Antimicrobial Cocktail

The current standard of care recommended by the CDC involves a combination of five specific medications [3][4]. These drugs are chosen because they work in different ways to kill the ameba or stop it from multiplying.

  1. Amphotericin B: This is the foundation of treatment. It works by punching holes in the ameba’s outer membrane, causing it to leak and die [5][6]. Because it is difficult for this drug to move from the blood into the brain, it is often given both intravenously (IV) and intrathecally (injected directly into the spinal fluid) [7][8].
  2. Miltefosine (Impavido): Originally developed for cancer and later used for tropical parasites, this drug is a critical addition to the PAM regimen [9][3]. It disrupts the ameba’s internal signaling and metabolism [3][10]. Miltefosine has been a common factor in the very few recorded cases of PAM survival [11][9]. It is commercially available under the brand name Impavido.
  3. Azithromycin & Fluconazole: These are commonly used antibiotics and antifungals that have shown the ability to help kill Naegleria fowleri when used in combination with the primary drugs [4][8].
  4. Rifampin: An antibiotic often used for tuberculosis, it is included here because it may help the other drugs work more effectively against the ameba [9][8].

Preparing for Treatment Toxicity

It is vital for families to know that this aggressive drug cocktail carries severe side effects. Amphotericin B, in particular, is highly toxic to the kidneys (nephrotoxicity) [5].

  • Patients receiving this regimen frequently experience significant kidney damage and may require emergency dialysis while in the ICU.
  • The ICU team is forced to walk a very fine line: they must use these highly toxic drugs to save the patient’s brain, while actively managing the resulting damage to the liver and kidneys. Do not be blindsided if the doctors inform you that the patient’s organs are struggling—this is an expected complication of fighting the infection.

Managing Brain Pressure

While the drugs work to kill the ameba, the most immediate danger to the patient is often cerebral edema—extreme swelling of the brain [12][13]. Because the skull is a rigid container, this swelling can cause the pressure inside (Intracranial Pressure, or ICP) to rise to dangerous levels [14].

  • ICP Monitoring: Doctors may place a small sensor or a drain (called an External Ventricular Drain or EVD) into the brain to measure pressure and drain excess fluid to relieve that pressure [15][16].
  • Therapeutic Hypothermia: This involve cooling the patient’s body to a lower-than-normal temperature (typically around 32°C–34°C or 89.6°F–93.2°F) [17][13]. The goal of this cooling, also called Targeted Temperature Management, is to protect the brain by reducing swelling and slowing down the metabolic rate of both the brain and the ameba [17][13].
  • Dexamethasone: This is a powerful steroid used to dampen the body’s own inflammatory response, which helps reduce the overall swelling in the brain tissue [12][8].

Securing the Drugs

Your medical team is likely in direct contact with the CDC Emergency Operations Center to ensure they are using the most current dosing [18][19]. If the hospital does not have Miltefosine (Impavido) in stock, families or doctors can check the manufacturer’s (Profounda) live online map to locate the nearest stocking facility immediately.

Common questions in this guide

What is the standard treatment for Primary Amebic Meningoencephalitis?
The CDC recommends an aggressive five-drug antimicrobial cocktail to treat PAM. This typically includes Amphotericin B, Miltefosine, Azithromycin, Fluconazole, and Rifampin, which work together to kill the ameba and stop it from multiplying.
Why is Amphotericin B given directly into the spinal fluid?
Amphotericin B is a powerful medication used to destroy the ameba's outer membrane, but it struggles to cross from the bloodstream into the brain. To ensure the medication reaches the infection, doctors often inject it directly into the spinal fluid, a process called intrathecal administration.
What are the side effects of the PAM medication cocktail?
The medications used to fight this aggressive ameba, particularly Amphotericin B, are highly toxic. Patients frequently experience severe kidney and liver damage as a side effect and may require emergency dialysis while in the intensive care unit.
How do doctors treat brain swelling caused by the ameba?
To manage severe brain swelling, doctors may use an external ventricular drain to relieve pressure inside the skull. They also frequently employ therapeutic hypothermia, which cools the body to reduce swelling and slow down the ameba, alongside powerful steroids like dexamethasone.
How can a hospital get Miltefosine if they don't have it?
If a hospital does not have Miltefosine in stock, doctors or family members can check the manufacturer's live online map to locate the nearest stocking facility. The medical team will also work with the CDC Emergency Operations Center to secure necessary medications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the patient currently receiving the full five-drug cocktail (Amphotericin B, Miltefosine, Azithromycin, Fluconazole, and Rifampin)?
  2. 2.Are we using intrathecal Amphotericin B (medication injected directly into the spinal fluid) in addition to the IV version?
  3. 3.How are we monitoring the pressure inside the skull, and what is the current ICP reading?
  4. 4.Are we using therapeutic hypothermia (cooling the body) to help with brain swelling, and what is our target temperature?
  5. 5.How are we monitoring and managing the potential kidney toxicity from the Amphotericin B?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Naegleria fowleri: Portrait of a Cerebral Killer.

    Phung NTN, Pham HT, Tran TT, et al.

    Diagnostics (Basel, Switzerland) 2025; (15(1)) doi:10.3390/diagnostics15010089.

    PMID: 39795618
  2. 2

    Primary Amoebic Meningoencephalitis by Naegleria fowleri: Pathogenesis and Treatments.

    Güémez A, García E

    Biomolecules 2021; (11(9)) doi:10.3390/biom11091320.

    PMID: 34572533
  3. 3

    Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case.

    Cope JR, Conrad DA, Cohen N, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (62(6)):774-6 doi:10.1093/cid/civ1021.

    PMID: 26679626
  4. 4

    trans-Cinnamic Acid Conjugated Gold Nanoparticles as Potent Therapeutics against Brain-Eating Amoeba Naegleria fowleri.

    Rajendran K, Anwar A, Khan NA, et al.

    ACS chemical neuroscience 2019; (10(6)):2692-2696 doi:10.1021/acschemneuro.9b00111.

    PMID: 30970208
  5. 5

    High-Throughput Screen of Microbial Metabolites Identifies F1FO ATP Synthase Inhibitors as New Leads for Naegleria fowleri Infection.

    Yuan A, Fong H, Nguyen JV, et al.

    ACS infectious diseases 2023; (9(12)):2622-2631 doi:10.1021/acsinfecdis.3c00437.

    PMID: 37943251
  6. 6

    Naegleria fowleri: pathogenesis, diagnosis, and treatment options.

    Grace E, Asbill S, Virga K

    Antimicrobial agents and chemotherapy 2015; (59(11)):6677-81 doi:10.1128/AAC.01293-15.

    PMID: 26259797
  7. 7

    A Fatal Case of Primary Amoebic Meningoencephalitis (PAM) Complicated with Diabetes Insipidus (DI): A Case Report and Review of the Literature.

    Mushtaq MZ, Mahmood SBZ, Aziz A

    Case reports in infectious diseases 2020; (2020()):4925819 doi:10.1155/2020/4925819.

    PMID: 32774948
  8. 8

    A Fatal Case of Primary Amoebic Meningoencephalitis from Recreational Waters.

    Hamaty E, Faiek S, Nandi M, et al.

    Case reports in critical care 2020; (2020()):9235794 doi:10.1155/2020/9235794.

    PMID: 32550028
  9. 9

    Naegleria fowleri: Diagnosis, Pathophysiology of Brain Inflammation, and Antimicrobial Treatments.

    Pugh JJ, Levy RA

    ACS chemical neuroscience 2016; (7(9)):1178-9 doi:10.1021/acschemneuro.6b00232.

    PMID: 27525348
  10. 10

    Inhibition of Fatty Acid Oxidation as a New Target To Treat Primary Amoebic Meningoencephalitis.

    Sarink MJ, Tielens AGM, Verbon A, et al.

    Antimicrobial agents and chemotherapy 2020; (64(8)) doi:10.1128/AAC.00344-20.

    PMID: 32513800
  11. 11

    Primary Amebic Meningoencephalitis in Children: A Report of Two Fatal Cases and Review of the Literature.

    Stowe RC, Pehlivan D, Friederich KE, et al.

    Pediatric neurology 2017; (70()):75-79 doi:10.1016/j.pediatrneurol.2017.02.004.

    PMID: 28389055
  12. 12

    Naegleria fowleri That Induces Primary Amoebic Meningoencephalitis: Rapid Diagnosis and Rare Case of Survival in a 12-Year-Old Caucasian Girl.

    Dunn AL, Reed T, Stewart C, Levy RA

    Laboratory medicine 2016; (47(2)):149-54 doi:10.1093/labmed/lmw008.

    PMID: 26984830
  13. 13

    Primary Amebic Meningoencephalitis: A Case Report.

    Chen M, Ruan W, Zhang L, et al.

    The Korean journal of parasitology 2019; (57(3)):291-294 doi:10.3347/kjp.2019.57.3.291.

    PMID: 31284352
  14. 14

    Primary amebic meningoencephalitis in children: A case report and literature review.

    Song B, Zheng J, Zhao D

    IDCases 2024; (37()):e02028 doi:10.1016/j.idcr.2024.e02028.

    PMID: 39109186
  15. 15

    Timing of neurosurgical interventions for intracranial hypertension: the intensivists' and neurosurgeons' view.

    Lin V, Hutchinson PJ, Kolias A, et al.

    Current opinion in critical care 2025; (31(2)):137-148 doi:10.1097/MCC.0000000000001243.

    PMID: 39991845
  16. 16

    External ventricular drainage for intracranial hypertension after traumatic brain injury: is it really useful?

    Moyer JD, Elouahmani S, Codorniu A, et al.

    European journal of trauma and emergency surgery : official publication of the European Trauma Society 2023; (49(3)):1227-1234 doi:10.1007/s00068-022-01903-4.

    PMID: 35169869
  17. 17

    A local case of fulminant primary amoebic meningoencephalitis due to Naegleria fowleri.

    McLaughlin A, O'Gorman T

    Rural and remote health 2019; (19(2)):4313 doi:10.22605/RRH4313.

    PMID: 30961348
  18. 18

    Advancing the understanding of Naegleria fowleri: Global epidemiology, phylogenetic analysis, and strategies to combat a deadly pathogen.

    Alanazi A, Younas S, Ejaz H, et al.

    Journal of infection and public health 2025; (18(4)):102690 doi:10.1016/j.jiph.2025.102690.

    PMID: 39913985
  19. 19

    A case report: primary amoebic meningoencephalitis in a young Zambian adult.

    Chomba M, Mucheleng'anga LA, Fwoloshi S, et al.

    BMC infectious diseases 2017; (17(1)):532 doi:10.1186/s12879-017-2638-8.

    PMID: 28764655

This page explains the aggressive ICU treatment protocol for Primary Amebic Meningoencephalitis (PAM) for educational purposes. Always rely on the critical care medical team and the CDC for emergency treatment decisions.

Get notified when new evidence is published on Primary amebic meningoencephalitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.